Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Physical activity, sedentary time and gain in overall and central body fat: 7-year follow-up of the ProActive trial cohort.

Golubic R, Wijndaele K, Sharp SJ, Simmons RK, Griffin SJ, Wareham NJ, Ekelund U, Brage S; ProActive Study Group.

Int J Obes (Lond). 2015 Jan;39(1):142-8. doi: 10.1038/ijo.2014.66. Epub 2014 Apr 15.

2.

Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.

Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C; PROactive Study Group.

Value Health. 2009 Jan-Feb;12(1):1-9. doi: 10.1111/j.1524-4733.2008.00403.x. Epub 2008 Jul 24.

3.

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.

PMID:
17593245
4.

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group.

Hepatology. 2004 Dec;40(6):1450-8.

PMID:
15565613
5.
6.

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group.

Gastroenterology. 2004 May;126(5):1302-11.

PMID:
15131791

Supplemental Content

Loading ...
Support Center